3 Diesel Engines Maker, Plastic Pipes and Adhesives Maker and Molecular Diagnostics Company Stocks With a Strong Future Roadmap: Kirloskar Oil Engines, Astral and Molbio Diagnostics
- November 6, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Kirloskar Oil Engines, Astral and Molbio Diagnostics: ROE of 13.2% to 15.9% and FY22 to FY26 revenue CAGR of 10.6% to 17.7%. Prices as of 5 Nov 2026.
Quick Answer
The three engine, pipe and molecular testing stocks to watch are Kirloskar Oil Engines, Astral and Molbio Diagnostics. Their return on equity ranges from 13.2% to 15.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.6% to 17.7%. Kirloskar Oil Engines leads on both return on equity at 15.9% and revenue growth at 17.7% a year. Prices are based on the 5 November 2026 close, and this article is educational, not investment advice.
Engine, pipe and molecular testing stocks let investors follow companies that serve a growing part of the Indian economy. Kirloskar Oil Engines, Astral and Molbio Diagnostics cover a diesel engines maker, a plastic pipes and adhesives maker and a molecular diagnostics company.
This list covers three engine, pipe and molecular testing stocks with complete current figures: Kirloskar Oil Engines, Astral and Molbio Diagnostics. Every figure comes from the latest reported financials and the 5 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Engine, Pipe and Molecular Testing Stocks?
Engine, pipe and molecular testing stocks are listed companies that make diesel engines, gensets and pumps, produce plumbing pipes, fittings and adhesives, and develop rapid molecular tests for infectious diseases. Their earnings depend on power equipment demand, construction activity and testing volumes.
Engine, Pipe and Molecular Testing Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Kirloskar Oil Engines | 1,592.4 | 28,722 | 53.7 | 44.4 | 15.9 | 1.48 |
| Astral | 1,388 | 38,267 | 66.5 | 36.4 | 13.2 | 0.06 |
| Molbio Diagnostics | 1,403.5 | 16,605 | 101.2 | 59.6 | 14.2 | 0.38 |
On valuation, all three trade at a P/E above their industry P/E, which reflects the growth the market already expects from them. Readers comparing engine, pipe and molecular testing stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Engine, Pipe and Molecular Testing Stocks Have a Strong Roadmap in India?
Engine, pipe and molecular testing stocks have a strong roadmap in India because rising demand for backup power and farm equipment, growing housing and water infrastructure work and wider access to molecular testing keep widening the market for these companies.
- Engines. Industries and farms need dependable power.
- Pipes. Housing and water projects need plumbing systems.
- Molecular testing. Fast tests reach more clinics.
Why Kirloskar Oil Engines Features Among These Engine, Pipe and Molecular Testing Stocks
Among the engine, pipe and molecular testing stocks on this list, Kirloskar Oil Engines, based in Pune, makes diesel and gas engines, generator sets, pumps and power solutions for industrial, farm and infrastructure use.
Revenue rose from Rs 4,049 crore in FY22 to Rs 7,772 crore in FY26, a compound annual growth rate of 17.7%. Net profit grew from Rs 171 crore in FY22 to Rs 558 crore in FY26, which works out to a compound annual growth rate of 34.4%.
In the June 2026 quarter, revenue grew 12.1% year on year to Rs 2,015 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 1.48 and a market capitalisation of Rs 28,722 crore. The stock trades at a P/E of 53.7, above the industry P/E of 44.4.
Roadmap: Backup power demand from data centres, telecom and infrastructure, a growing exports business and new alternative-fuel engines give it several tracks for growth. A large service network helps it hold on to customers across product cycles.
What to watch: Watch order intake from data centres and the pace of new product launches in cleaner fuels.
Why Astral Features Among These Engine, Pipe and Molecular Testing Stocks
Among the power equipment, building and diagnostics shares on this list, Astral is a leading maker of plastic piping systems and building products, with CPVC and PVC pipes, adhesives, sealants and bathware sold through a wide distribution network.
In the June 2026 quarter, revenue grew 16.1% year on year to Rs 1,591 crore, while net profit rose 51.8% to Rs 120 crore. Revenue rose from Rs 4,429 crore in FY22 to Rs 6,616 crore in FY26, a compound annual growth rate of 10.6%.
Net profit grew from Rs 460 crore in FY23 to Rs 535 crore in FY26, which works out to a compound annual growth rate of 5.2%. The company has a return on equity of 13.2%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 38,267 crore. The stock trades at a P/E of 66.5, above the industry P/E of 36.4.
Roadmap: The company has widened from plumbing pipes to adhesives, paints and bathware, which lifts revenue per customer. Capacity additions and an extensive dealer network position it well for housing and infrastructure demand.
What to watch: Watch PVC resin price trends and growth in the adhesives and paints businesses.
Why Molbio Diagnostics Features Among These Engine, Pipe and Molecular Testing Stocks
Among the three companies on this list, Molbio Diagnostics, based in Goa, develops the Truenat platform, a portable molecular diagnostics system that delivers lab-grade PCR results at the point of care, with strong use in tuberculosis testing.
The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6.
Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%.
Roadmap: Its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.
What to watch: Order timing from public health programmes can be lumpy, so look at annual rather than single-quarter trends.
Kirloskar Oil Engines vs Astral vs Molbio Diagnostics on Key Financials
The table below sets the three engine, pipe and molecular testing stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Kirloskar Oil Engines | 4,049 | 7,772 | 17.7% | 558 | 7.2% |
| Astral | 4,429 | 6,616 | 10.6% | 535 | 8.1% |
| Molbio Diagnostics | 782 | 1,455 | 16.8% | 164 | 11.3% |
Kirloskar Oil Engines posts the highest return on equity in this group at 15.9%. Kirloskar Oil Engines combines the largest FY26 revenue at Rs 7,772 crore with the fastest revenue growth, a 17.7% compound annual rate. A useful habit with engine, pipe and molecular testing stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Engine, Pipe and Molecular Testing Stocks
Every theme carries risks that deserve a check before any decision. For these engine, pipe and molecular testing stocks, the main points are: Long-term power equipment, building and diagnostics shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Input costs. Metal and material prices can move margins.
- Housing cycles. Real estate and building demand can vary with rates and sentiment.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter engine, pipe and molecular testing stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Engine, Pipe and Molecular Testing Stocks
Engine, pipe and molecular testing stocks reward investors who follow demand trends, order books and margins together. Kirloskar Oil Engines, Astral and Molbio Diagnostics each have a clear plan to grow. Based on the 5 November 2026 close, Kirloskar Oil Engines trades at Rs 1,592.4, Astral at Rs 1,388 and Molbio Diagnostics at Rs 1,403.5. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these engine, pipe and molecular testing stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track engine, pipe and molecular testing stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are engine, pipe and molecular testing stocks?
Ans. Engine, pipe and molecular testing stocks are listed companies that make diesel engines, gensets and pumps, produce plumbing pipes, fittings and adhesives, and develop rapid molecular tests for infectious diseases. Their earnings depend on power equipment demand, construction activity and testing volumes. This list looks at three of them, Kirloskar Oil Engines, Astral and Molbio Diagnostics, using reported FY22 to FY26 financials and the 5 November 2026 closing prices.
Which engine, pipe and molecular testing stocks are covered in this list?
Ans. This list covers Kirloskar Oil Engines, Astral and Molbio Diagnostics. Based on the 5 November 2026 close, Kirloskar Oil Engines traded at Rs 1,592.4, Astral at Rs 1,388 and Molbio Diagnostics at Rs 1,403.5. Their return on equity ranges from 13.2% to 15.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.6% to 17.7%.
Why do engine, pipe and molecular testing stocks have a strong future roadmap in India?
Ans. Engine, pipe and molecular testing stocks have a strong roadmap in India because rising demand for backup power and farm equipment, growing housing and water infrastructure work and wider access to molecular testing keep widening the market for these companies. The main drivers are as follows. Engines. Industries and farms need dependable power. Pipes. Housing and water projects need plumbing systems. Molecular testing. Fast tests reach more clinics. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Kirloskar Oil Engines performed financially?
Ans. Revenue rose from Rs 4,049 crore in FY22 to Rs 7,772 crore in FY26, a compound annual growth rate of 17.7%. Net profit grew from Rs 171 crore in FY22 to Rs 558 crore in FY26, which works out to a compound annual growth rate of 34.4%. In the June 2026 quarter, revenue grew 12.1% year on year to Rs 2,015 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 1.48 and a market capitalisation of Rs 28,722 crore. The stock trades at a P/E of 53.7, above the industry P/E of 44.4. Looking ahead, backup power demand from data centres, telecom and infrastructure, a growing exports business and new alternative-fuel engines give it several tracks for growth. A large service network helps it hold on to customers across product cycles.
How has Astral performed financially?
Ans. Revenue rose from Rs 4,429 crore in FY22 to Rs 6,616 crore in FY26, a compound annual growth rate of 10.6%. Net profit grew from Rs 460 crore in FY23 to Rs 535 crore in FY26, which works out to a compound annual growth rate of 5.2%. In the June 2026 quarter, revenue grew 16.1% year on year to Rs 1,591 crore, while net profit rose 51.8% to Rs 120 crore. The company has a return on equity of 13.2%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 38,267 crore. The stock trades at a P/E of 66.5, above the industry P/E of 36.4. Looking ahead, the company has widened from plumbing pipes to adhesives, paints and bathware, which lifts revenue per customer. Capacity additions and an extensive dealer network position it well for housing and infrastructure demand.
How has Molbio Diagnostics performed financially?
Ans. Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6. Looking ahead, its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.
What risks should investors check before buying engine, pipe and molecular testing stocks?
Ans. Investors should check a few risks before buying engine, pipe and molecular testing stocks. Input costs. Metal and material prices can move margins. Housing cycles. Real estate and building demand can vary with rates and sentiment. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of engine, pipe and molecular testing stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 5 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
